NeuroMab™ Anti-TREM2 Antibody, Clone NR65P
A functional antibody raised against Human, Cynomolgus Monkey TREM2.
- Host Species:
- Humanized
- Species Reactivity:
- Human; Cynomolgus Monkey
- Applications:
- FC; ELISA; In Vitro; Agonist; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Shipping
Storage
Research Use Only
Figure 1 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity of Fc variant antibodies co-cultured with BWZ reporter cells and THP-1 cells at a ratio of 1:1 for 6 hours.
Figure 2 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity after 6 hours incubation with Fc variant of anti-TREM2 antibody.
Figure 3 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change in C3b deposition on HEK expressing TREM2 cell lines of AL2p Fc variants relative to human IgG1 isotype control antibody at 10 μg/mL.
Figure 4 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change in C3b deposition of AL2p affinity matured variants with the listed Fc mutations relative to their parental IgG1 Fc variants.
Figure 5 shows the increase in activity of soluble anti-TREM2 antibody.
Figure 6 shows the increased activity of soluble anti-TREM2 antibodies.
Figure 7 shows sTREM2 secreted by primary human dendritic cells from donor 534 within 48 hours of incubation with anti-TREM2 or control antibody.
Figure 8 shows that after incubation of primary human dendritic cells from donor 534 with anti-TREM2 or control antibody, there was no change in cell number.
Figure 9 shows plasma sTREM2 as a percentage of baseline levels following a single injection of 15 mg/kg of the TREM2 antibodies AL2p-47 huIgG1 , AL2p-47 huIgG1 ASPSEG, AL2p-58 huIgG1 , or control huIgG1.
Figure 10 depicts increased viability (increased cellular ATP) after stimulation of primary human macrophages.
Figure 11 shows Western blot analysis of Dapl2 phosphorylation in WT or TREM2 Bac-Tg mouse peritoneal macrophages treated with AL2p-58 huIgG1 , AL2p-58 huIgG1 PSEG or control huIgG1.
Publications (0)